coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

被引：8

作者：

Paolo A Ascierto

Grant A. McArthur

Brigitte Dréno

James Larkin

Gabriella Liszkay

Michele Maio

Mario Mandala

Lev Demidov

Daniil Stroyakovskiy

Luc Thomas

Luis de la Cruz-Merino

Victoria Atkinson

Caroline Dutriaux

Claus Garbe

Ilsung Chang

Stephen P. Hack

Antoni Ribas

机构：

[1] Istituto Nazionale Tumori Fondazione G. Pascale,

[2] Peter MacCallum Cancer Centre,undefined

[3] Hôtel Dieu Place Alexis Ricordeau,undefined

[4] The Royal Marsden Hospital,undefined

[5] National Institute of Oncology,undefined

[6] Azienda Ospedaliera Universitaria Senese,undefined

[7] Papa Giovanni XXIII Hospital,undefined

[8] N.N. Blokhin Russian Cancer Research Center,undefined

[9] Moscow City Oncology Hospital 62,undefined

[10] Centre Hospitalier Lyon Sud,undefined

[11] Hospital Universitario Virgen Macarena,undefined

[12] Princess Alexandra Hospital,undefined

[13] Hopital Saint André,undefined

[14] University of Tübingen,undefined

[15] Genentech,undefined

[16] Inc,undefined

[17] Jonsson Comprehensive Cancer Center at the University of California,undefined

[18] Los Angeles,undefined

来源：

Journal of Translational Medicine | / 13卷 / Suppl 1期

关键词：

Overall Survival; Metastatic Melanoma; Vemurafenib; Creatine Phosphokinase; BRAF Inhibitor;

D O I：

10.1186/1479-5876-13-S1-O4

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Reinhard Dummer
Michèle Welti
Egle Ramelyte
Journal of Translational Medicine, 21
[32] Randomized, double-blind, placebo-controlled phase 3 study of ibrutinib plus rituximab in patients with previously untreated marginal zone lymphoma (MZL).
Noy, Ariela
Hughes, Stephanie
Biggar, Erin
Bogdan, Matthew
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[33] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC
de Wit, M.
Laack, E.
Schulz, C.
Wolff, T.
Rueckert, A.
Reck, M.
Faehling, M.
Fischer, J.
STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S24 - S24
[34] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC
Laack, H. -E.
Schulz, C.
Wolff, T.
Rueckert, A.
Reck, M.
Faehling, M.
Fischer, J. R.
de Wit, M.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 186 - 187
[35] Phase 3, Double-Blind, Placebo-Controlled Study of MEDI4736 After Chemoradiation in Stage III, Locally Advanced, Unresectable NSCLC (PACIFIC)
Cho, Byoung Chul
Kim, Joo-Hang
Villegas, Augusto
Frusch, Nicolas
Murakami, Shuji
Shi, Kelvin
Ibrahim, Ramy
Ballas, Marc
Antonia, Scott J.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S668 - S668
[36] BRIM8: A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419).
Lewis, Karl D.
Maio, Michele
Mandala, Mario
Nelson, Betty J.
Goodman, Grant R.
Schadendorf, Dirk
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[37] Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study
Xu, Binghe
Li, Wei
Zhang, Qingyuan
Li, Qiao
Wang, Xiaojia
Li, Huiping
Sun, Tao
Yin, Yongmei
Zheng, Hong
Feng, Jifeng
Zhu, Huaqi
Siddiqui, Asna
Macharia, Harrison
Knott, Adam
BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (03) : 503 - 513
[38] Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study
Binghe Xu
Wei Li
Qingyuan Zhang
Qiao Li
Xiaojia Wang
Huiping Li
Tao Sun
Yongmei Yin
Hong Zheng
Jifeng Feng
Huaqi Zhu
Asna Siddiqui
Harrison Macharia
Adam Knott
Breast Cancer Research and Treatment, 2023, 197 : 503 - 513
[39] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC
Paz-Ares, L.
Villegas, A.
Daniel, D.
Baz, D. V.
Murakami, S.
Hui, R.
Yokoi, T.
Chiappori, A.
Lee, K. H.
de Wit, M.
Cho, B. C.
Bourhaba, M.
Quantin, X.
Tokito, T.
Mekhail, T.
Planchard, D.
Jiang, H.
Huang, Y.
Dennis, P. A.
Ozguroglu, M.
ANNALS OF ONCOLOGY, 2017, 28
[40] A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN
Wang, Luhua
Chen, Ming
Kato, Ken
Wyrwicz, Lucjan
Smyth, Elizabeth Catherine
Jiang, Anastasia
Zhang, Di
Robbins, Scott H.
He, Philip
Negro, Alejandra
Saba, Nabil F.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

← 1 2 3 4 5 →